Form 4: Merck GC Jennifer Zachary Acquires Shares

Merck & Co.'s EVP and General Counsel, Jennifer Zachary, acquired 11,583 shares of common stock at $107.4 per share following the vesting of performance share units.

Summary

• Jennifer Zachary, Executive Vice President and General Counsel of Merck & Co., Inc., acquired 11,583 shares of common stock.
• The transaction occurred on January 26, 2026, with shares valued at $107.4 each.
• These shares were distributed as net after-tax shares upon the satisfaction of performance criteria for performance share units that were granted on March 31, 2023.
• The performance shares were paid out at 94% of their target awards.
• The acquired shares include dividends that accrued over a three-year performance period, which concluded on December 31, 2025.
• Following this transaction, Jennifer Zachary's beneficial ownership of Merck & Co. common stock totals 68,915.671 shares.
• Her total holdings also incorporate shares obtained through dividend reinvestment transactions.

Sentiment

Score: 7

Explanation: The filing indicates a positive outcome for the executive's performance-based compensation, with shares vesting at 94% of target, suggesting good company performance against internal metrics. This aligns executive interests with shareholders.

Positives

• Performance share units were paid out at 94% of target awards, indicating strong performance against the established criteria.
• The acquisition increases the executive's direct ownership in the company, further aligning her interests with those of shareholders.
• The shares include accrued dividends, reflecting additional value generated over the three-year performance period.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies. It reflects the company's compensation structure and the executive's vested interest.

Comparison to Industry Standards

• This is a standard executive compensation payout via performance share units, a common practice in large pharmaceutical companies and across various industries.
• The 94% payout suggests solid, though not exceptional, performance against internal targets, which is generally in line with typical corporate performance metrics for executive incentives.
• No specific comparable companies or projects are mentioned in the filing.

Related Party Transactions

• This transaction represents an executive compensation payout, which is a standard, disclosed related-party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to increased stock ownership. The 94% payout suggests the company met most of its performance targets, which is generally positive for shareholder value.
• Employees: Reflects the company's executive compensation structure and performance incentives.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event where performance share units vested at 94% of target. While the payout indicates solid performance against internal metrics and increases executive alignment with shareholders, it does not present new material information that would fundamentally alter the investment thesis for Merck & Co. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Merck & Co., MRK, Jennifer Zachary, EVP General Counsel, Stock Acquisition, Performance Share Units, Insider Trading, Executive Compensation, SEC Form 4